ASH-话题@MedSci

#ASH#

242篇内容 | 2098人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1301318, encodeId=8c4a130131868, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显, objectType=article, longId=203520, objectId=4ff9203520a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff9203520a1, replyNumber=0, likeNumber=45, createdTime=2020-11-20, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff9203520a1, moduleTitle=NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff9203520a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301317, encodeId=29df130131e77, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, objectType=article, longId=203274, objectId=cfcb2032e4c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfcb2032e4c1, replyNumber=0, likeNumber=80, createdTime=2020-11-13, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfcb2032e4c1, moduleTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfcb2032e4c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301316, encodeId=2dbb1301316f4, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASH 2020：研究性新药Alvocidib治疗复发难治急性髓细胞白血病（AML）, objectType=article, longId=203075, objectId=8c062030e5cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c062030e5cf, replyNumber=0, likeNumber=74, createdTime=2020-11-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c062030e5cf, moduleTitle=ASH 2020：研究性新药Alvocidib治疗复发难治急性髓细胞白血病（AML）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c062030e5cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301315, encodeId=8f311301315b0, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASHG 2020：AT-007治疗半乳糖血症, objectType=article, longId=202382, objectId=c878202382f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c878202382f1, replyNumber=0, likeNumber=58, createdTime=2020-10-24, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c878202382f1, moduleTitle=ASHG 2020：AT-007治疗半乳糖血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c878202382f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301314, encodeId=a4d313013148f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Efruxifermin（EFX）治疗NASH：已获欧洲药品管理局的“优先药物称号”（PRIME）, objectType=article, longId=202223, objectId=a05920222388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a05920222388, replyNumber=0, likeNumber=63, createdTime=2020-10-18, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a05920222388, moduleTitle=Efruxifermin（EFX）治疗NASH：已获欧洲药品管理局的“优先药物称号”（PRIME）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a05920222388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301313, encodeId=19c51301313e8, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Lanifibranor治疗NASH：FDA授予“突破性疗法称号”, objectType=article, longId=202052, objectId=b0b52020520a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0b52020520a, replyNumber=0, likeNumber=79, createdTime=2020-10-15, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0b52020520a, moduleTitle=Lanifibranor治疗NASH：FDA授予“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0b52020520a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301312, encodeId=634d1301312c9, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=FXR激动剂ASC42治疗NASH：美国FDA已批准IND, objectType=article, longId=202037, objectId=84d120203ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84d120203ed5, replyNumber=0, likeNumber=69, createdTime=2020-10-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84d120203ed5, moduleTitle=FXR激动剂ASC42治疗NASH：美国FDA已批准IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84d120203ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301311, encodeId=45b01301311d6, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）, objectType=article, longId=198731, objectId=37c9198e311c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37c9198e311c, replyNumber=0, likeNumber=61, createdTime=2020-08-06, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37c9198e311c, moduleTitle=RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37c9198e311c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301310, encodeId=8fbc130131033, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=非酒精性脂肪性肝炎（NASH）新药Namodenoson：所有功效指标均得到显着且持续改善, objectType=article, longId=196884, objectId=c1dc196884ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1dc196884ba, replyNumber=0, likeNumber=69, createdTime=2020-07-03, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1dc196884ba, moduleTitle=非酒精性脂肪性肝炎（NASH）新药Namodenoson：所有功效指标均得到显着且持续改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1dc196884ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301309, encodeId=5a3a13013093a, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=非酒精性脂肪性肝炎（NASH）：歌礼生物的ASC40显著降低肝脏脂肪，响应率达61％, objectType=article, longId=196200, objectId=2de719620026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2de719620026, replyNumber=0, likeNumber=58, createdTime=2020-06-22, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2de719620026, moduleTitle=非酒精性脂肪性肝炎（NASH）：歌礼生物的ASC40显著降低肝脏脂肪，响应率达61％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2de719620026)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301308, encodeId=3754130130890, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=非酒精性脂肪性肝炎（NASH）迎来新进展：lanifibranor达到期中研究的主要终点, objectType=article, longId=196006, objectId=cc5f1960069e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc5f1960069e, replyNumber=0, likeNumber=0, createdTime=2020-06-18, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc5f1960069e, moduleTitle=非酒精性脂肪性肝炎（NASH）迎来新进展：lanifibranor达到期中研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc5f1960069e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301307, encodeId=307c130130e5c, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=索马鲁肽挑战NASH初获成功，过半患者NASH消除症状, objectType=article, longId=193714, objectId=7a09193e1466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a09193e1466, replyNumber=0, likeNumber=92, createdTime=2020-05-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a09193e1466, moduleTitle=索马鲁肽挑战NASH初获成功，过半患者NASH消除症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a09193e1466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301306, encodeId=347f130130626, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=JAMA Intern Med：SMASH行动对山东省盐摄入及血液的影响, objectType=article, longId=193133, objectId=6dbf1931332a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dbf1931332a, replyNumber=0, likeNumber=73, createdTime=2020-04-30, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dbf1931332a, moduleTitle=JAMA Intern Med：SMASH行动对山东省盐摄入及血液的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dbf1931332a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301305, encodeId=f687130130576, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=周剑峰教授：疫情期间中国淋巴瘤患者治疗经验与ASH更新诊治指导建议分享, objectType=article, longId=192444, objectId=c68919244416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c68919244416, replyNumber=0, likeNumber=81, createdTime=2020-04-19, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c68919244416, moduleTitle=周剑峰教授：疫情期间中国淋巴瘤患者治疗经验与ASH更新诊治指导建议分享, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c68919244416)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301304, encodeId=304d1301304a6, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=3期临床新数据证明：THR-β激动剂Resmetirom可显着降低NASH患者的肝脏脂肪和纤维化程度, objectType=article, longId=192378, objectId=5c501923e835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c501923e835, replyNumber=0, likeNumber=79, createdTime=2020-04-17, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c501923e835, moduleTitle=3期临床新数据证明：THR-β激动剂Resmetirom可显着降低NASH患者的肝脏脂肪和纤维化程度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c501923e835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301303, encodeId=83eb130130379, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功, objectType=article, longId=191736, objectId=e771191e364a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e771191e364a, replyNumber=0, likeNumber=70, createdTime=2020-04-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e771191e364a, moduleTitle=A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e771191e364a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301302, encodeId=718a13013029b, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Hanmi的NASH候选药物HM15211治疗硬化性胆管炎，获得FDA孤儿药称号, objectType=article, longId=189674, objectId=42571896e458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42571896e458, replyNumber=0, likeNumber=78, createdTime=2020-03-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42571896e458, moduleTitle=Hanmi的NASH候选药物HM15211治疗硬化性胆管炎，获得FDA孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42571896e458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301301, encodeId=278513013011c, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=歌礼新药治疗非酒精性脂肪肝炎（NASH）即将进入临床, objectType=article, longId=188487, objectId=0b7518848e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b7518848e5b, replyNumber=0, likeNumber=79, createdTime=2020-02-22, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b7518848e5b, moduleTitle=歌礼新药治疗非酒精性脂肪肝炎（NASH）即将进入临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b7518848e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301300, encodeId=05f413013008c, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Clinica Chimica Acta：基于circRNA芯片筛选Kashin-Beck病和骨关节炎患者之间差异表达的circRNA, objectType=article, longId=187634, objectId=4b1118e6349f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b1118e6349f, replyNumber=0, likeNumber=60, createdTime=2020-02-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b1118e6349f, moduleTitle=Clinica Chimica Acta：基于circRNA芯片筛选Kashin-Beck病和骨关节炎患者之间差异表达的circRNA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b1118e6349f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301299, encodeId=94fb130129927, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Int J Radia Oncol：癌症放疗的痛苦，未来有望通过FLASH质子放疗解决, objectType=article, longId=186343, objectId=600b18634395, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=600b18634395, replyNumber=0, likeNumber=64, createdTime=2020-01-18, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=600b18634395, moduleTitle=Int J Radia Oncol：癌症放疗的痛苦，未来有望通过FLASH质子放疗解决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=600b18634395)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASH

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#ASH#

NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显

2020-11-20

kksonne (审核中...)

前往app查看评论内容

#ASH#

FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）

2020-11-13

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASH 2020：研究性新药Alvocidib治疗复发难治急性髓细胞白血病（AML）

2020-11-09

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASHG 2020：AT-007治疗半乳糖血症

2020-10-24

kksonne (审核中...)

前往app查看评论内容

#ASH#

Efruxifermin（EFX）治疗NASH：已获欧洲药品管理局的“优先药物称号”（PRIME）

2020-10-18

kksonne (审核中...)

前往app查看评论内容

#ASH#

Lanifibranor治疗NASH：FDA授予“突破性疗法称号”

2020-10-15

kksonne (审核中...)

前往app查看评论内容

#ASH#

FXR激动剂ASC42治疗NASH：美国FDA已批准IND

2020-10-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）

2020-08-06

kksonne (审核中...)

前往app查看评论内容

#ASH#

非酒精性脂肪性肝炎（NASH）新药Namodenoson：所有功效指标均得到显着且持续改善

2020-07-03

kksonne (审核中...)

前往app查看评论内容

#ASH#

非酒精性脂肪性肝炎（NASH）：歌礼生物的ASC40显著降低肝脏脂肪，响应率达61％

2020-06-22

kksonne (审核中...)

前往app查看评论内容

#ASH#

非酒精性脂肪性肝炎（NASH）迎来新进展：lanifibranor达到期中研究的主要终点

2020-06-18

kksonne (审核中...)

前往app查看评论内容

#ASH#

索马鲁肽挑战NASH初获成功，过半患者NASH消除症状

2020-05-09

kksonne (审核中...)

前往app查看评论内容

#ASH#

JAMA Intern Med：SMASH行动对山东省盐摄入及血液的影响

2020-04-30

kksonne (审核中...)

前往app查看评论内容

#ASH#

周剑峰教授：疫情期间中国淋巴瘤患者治疗经验与ASH更新诊治指导建议分享

2020-04-19

kksonne (审核中...)

前往app查看评论内容

#ASH#

3期临床新数据证明：THR-β激动剂Resmetirom可显着降低NASH患者的肝脏脂肪和纤维化程度

2020-04-17

kksonne (审核中...)

前往app查看评论内容

#ASH#

A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功

2020-04-10

kksonne (审核中...)

前往app查看评论内容

#ASH#

Hanmi的NASH候选药物HM15211治疗硬化性胆管炎，获得FDA孤儿药称号

2020-03-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

歌礼新药治疗非酒精性脂肪肝炎（NASH）即将进入临床

2020-02-22

kksonne (审核中...)

前往app查看评论内容

#ASH#

Clinica Chimica Acta：基于circRNA芯片筛选Kashin-Beck病和骨关节炎患者之间差异表达的circRNA

2020-02-08

kksonne (审核中...)

前往app查看评论内容

#ASH#

Int J Radia Oncol：癌症放疗的痛苦，未来有望通过FLASH质子放疗解决

2020-01-18

科室
- - 订阅+
  - 更多科室
工具
服务